Targeting Cancer with CAR T Cells Using Small Molecule 'Flags'

This patent describes a method to treat cancer by giving a patient special immune cells (CAR T cells) that are trained to find a specific 'flag' molecule, and then also giving them a drug molecule attached to that same 'flag' in varying amounts or forms.

What it covers

This patent details a method for treating cancer by combining CAR T cell therapy with targeted drug delivery. First, a patient receives CAR T cells, which are engineered immune cells designed to recognize a specific 'targeting moiety' (a molecular tag). Then, the patient receives a compound that consists of a 'small molecule ligand' (a drug-like molecule) linked to that same 'targeting moiety' by a 'linker'. The key innovation involves administering this compound in either different doses (Claim 1) or as different versions of the compound (different 'conjugates') (Claims 2 and 3). For example, a patient might receive CAR T cells that recognize a folate-based targeting moiety, and then receive different doses of a folate-linked small molecule drug to direct the CAR T cells to cancer cells.

What it doesn't cover

• —CAR T cell therapies that target natural antigens on cancer cells without the use of an externally administered small molecule conjugate.
• —Small molecule drug delivery systems that do not involve CAR T cells specifically directed to the small molecule's targeting moiety.
• —Administering the small molecule ligand linked to a targeting moiety in a single, unchanging dose, or as only one type of conjugate.
• —CAR T cells that are not specifically engineered to recognize the same targeting moiety as the administered small molecule conjugate.
• —Methods where the small molecule ligand is not linked to a targeting moiety by a linker, as described in the claims.

The clever bit

The novelty lies in the coordinated approach: engineering CAR T cells to recognize a specific molecular 'flag' and then using a small molecule drug attached to that exact 'flag' to guide the CAR T cells to the cancer. The ability to vary the dose or type of this 'flagged' drug allows for fine-tuning the immune response.

Why it matters

CAR T cell therapy is a powerful new way to fight cancer, but it can sometimes cause severe side effects or struggle to find all cancer cells. This patent aims to make CAR T cell therapy more precise and potentially more effective by guiding the immune cells to cancer cells using a specially designed 'flag' molecule. By controlling the doses or types of these 'flag' molecules, doctors might be able to better manage the treatment and its effects.

Real-world examples

• 1.CAR T cell therapies for blood cancers (e.g., Kymriah, Yescarta)
• 2.Targeted drug delivery systems using small molecules like folate to deliver chemotherapy
• 3.Experimental cancer treatments combining immunotherapy with targeted agents